Gilead unit to buy Pennsylvania-based cell therapy spinout


Tmunity, which is being acquired by Gilead's Kite, suffered a major setback last year when two patients died in a clinical trial testing the company's prostate cancer cell therapy.

Previous CFPB director calls Wells Fargo's $3.7 billion settlement an 'initial step'
Next Texas 100: Influential professionals to watch in 2023